GlassScriptPhysician profile
William D Coleman
NPI 1275889503
$21,725.82
in general payments reported to CMS, 2019-2025
15 companies · $5,557 in 2025
The $5,557 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $163 · 2021: $7,819 · 2022: $6,207 · 2023: $869 · 2024: $579 · 2025: $5,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Food and Beverage: $1,987 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Food and Beverage | $1,987.01 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $17,596.66 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $2,188.76 | 2021-2025 | Total30, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $375.43 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $355.03 | 2022-2024 | Infuse, Miebo, Biotrue One Day |
| Tarsus Pharmaceuticals, INC. | $266.32 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $214.40 | 2020-2023 | Acuvue |
| Oyster Point Pharma, INC. | $178.02 | 2022-2025 | Tyrvaya |
| Astellas Pharma US INC | $121.60 | 2025 | Izervay |
| Shire North American Group INC | $117.49 | 2019 | |
| Sun Pharmaceutical Industries INC. | $107.92 | 2020-2024 | Cequa |
| Harrow Eye, LLC | $78.65 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $46.52 | 2021-2022 | |
| Abbvie INC. | $43.65 | 2022 | |
| Rxsight INC | $18.20 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Kala Pharmaceuticals, INC. | $17.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.